BerGenBio ASA: Results for the Third Quarter 2018
· Phase II data in NSCLC with bemcentinib/KEYTRUDA combination: First stage of trial in previously treated patients reported 40% ORR and ca. 6 months median PFS in AXL positive patients, stage 2 actively enrolling patients · Additional NSCLC data: Bemcentinib/TARCEVA phase II combination trial in first line EGFRm patients reported that median PFS has surpassed that of TARCEVA monotherapy, encouraging efficacy reported in combination trial with docetaxel in later line patients · Pipeline update: IND filed for AXL antibody BGB149Bergen, Norway, 13 November 2018 – BerGenBio ASA (OSE: